Sitagliptin

Generic Name: Sitagliptin

Brand Names: Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅F_₆N_₅O

CAS Number: 486460-32-6

Unique Ingredient Identifier: QFP0P1DV7Z

Background: Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.

Indication: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.

It is also used in combination with metformin or ertugliflozin.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LIXISENATIDE AVE0010
Drug: Sitagliptin
Drug: Insulin glargine HOE901

First Posted Date: 2014-07-25

Last Posted Date: 2016-10-05

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT02200991

Locations: 🇯🇵
Investigational Site Number 392-122, Kobe-shi, Japan
🇯🇵
Investigational Site Number 392-101, Kyoto-shi, Japan
🇯🇵
Investigational Site Number 392-119, Nerima-ku, Japan

and more 17 locations

Correlation Between Plasma- and Endothelial DPP-4 Activity

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: sitagliptin

First Posted Date: 2014-07-17

Last Posted Date: 2017-09-11

Lead Sponsor: University Hospital, Gentofte, Copenhagen

Target Recruit Count: 20

Registration Number: NCT02192853

Locations: 🇩🇰
Diabetes Research Division, Department of Endocrinology, Gentofte Hospital, Hellerup, Denmark

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Chiglitazar
Drug: Sitagliptin

First Posted Date: 2014-06-25

Last Posted Date: 2019-10-25

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 740

Registration Number: NCT02173457

Locations: 🇨🇳
The Second Artillery General Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳
The First People's Hospital of Yueyang, Yueyang, Hunan, China
🇨🇳
The Affiliated Hospital of Inner Mongolia, Hohhot, Inner Mongolia, China

and more 34 locations

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Sitagliptin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172196

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Not Applicable

Completed

Conditions: Hypertension
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Sitagliptin
Drug: Aprepitant
Other: Mixed Meal Test (MMT)

First Posted Date: 2014-05-05

Last Posted Date: 2022-03-02

Lead Sponsor: Vanderbilt University

Target Recruit Count: 106

Registration Number: NCT02130687

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Drug: Sitagliptin
Drug: Exercise

First Posted Date: 2014-04-30

Last Posted Date: 2017-07-27

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT02127047

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Phase 4

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Sitagliptin
Drug: Placebo

First Posted Date: 2014-04-24

Last Posted Date: 2020-05-08

Lead Sponsor: Vanderbilt University

Target Recruit Count: 23

Registration Number: NCT02122380

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2409021
Drug: Placebo
Drug: Sitagliptin
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2014-04-10

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 174

Registration Number: NCT02111096

Locations: 🇺🇸
Midwest CRC, Crystal Lake, Illinois, United States
🇺🇸
Iderc, P.L.C., Des Moines, Iowa, United States
🇺🇸
Cotton O'Neil Clinic, Topeka, Kansas, United States

and more 27 locations

DPP-4 Inhibition, Incretins and Islet Function

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Sitagliptin
Drug: Vildagliptin
Drug: Saxagliptin

First Posted Date: 2014-03-17

Last Posted Date: 2017-08-23

Lead Sponsor: Lund University

Target Recruit Count: 24

Registration Number: NCT02089438

Locations: 🇸🇪
Clinical Research Department, Lund, Sweden

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide
Drug: sitagliptin

First Posted Date: 2014-03-04

Last Posted Date: 2017-05-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1059

Registration Number: NCT02077946

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy